Prediction of Latency Interval in Patients With Preterm Prelabor Rupture of Membranes

October 2, 2026 updated by: Ahmed Mohammed Elmaraghy, Ain Shams Maternity Hospital

Myometrial Thickness as a Predictor of Latency Interval in Preterm Prelabor Rupture of Membranes: A Prospective Cohort Study

Prediction of latency interval in Preterm prelabor rupture of membranes (PPROM) remains challenging in clinical practice, Myometrial thickness (MT) has emerged as a potential ultrasound marker for predicting the risk of preterm labor.

This study aims to prospectively evaluate the correlation between MT measurements at multiple uterine sites and latency interval in women with PPROM.

Study Overview

Status

Not yet recruiting

Detailed Description

PPROM is a major obstetric complication, occurring in approximately 3% of pregnancies and accounting for 30-40% of preterm births worldwide. It is defined as rupture of the fetal membranes before the onset of labor and prior to 37 weeks of gestation, creating a clinical dilemma that balances the risks of prematurity against the dangers of prolonged membrane rupture. The condition carries significant perinatal morbidity and mortality, including respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, and neonatal sepsis, alongside maternal complications such as chorioamnionitis and postpartum hemorrhage.

The latency period, defined as the interval between membrane rupture and delivery, is a critical determinant of neonatal outcomes. A longer latency permits completion of antenatal corticosteroid therapy for fetal lung maturation and antibiotic prophylaxis, thereby improving neonatal prognosis. Conversely, prolonged latency increases the risk of ascending infection, chorioamnionitis, and placental abruption, necessitating careful and individualized management, Current evidence indicates that approximately 50% of affected women deliver within 48 hours, and 70-90% within one week of membrane rupture, although latency may occasionally extend for several weeks in cases of very early PPROM according to recommendations of the American College of Obstetricians and Gynecologists.

Standard management between 24 and 34 weeks includes hospitalization, antibiotic prophylaxis, antenatal corticosteroids, and magnesium sulfate for neuroprotection before 32 weeks, alongside close maternal-fetal surveillance. Despite these well-established interventions, accurate prediction of latency duration remains a significant clinical challenge. Traditional predictors such as gestational age at rupture, amniotic fluid volume, cervical length, fetal fibronectin, and inflammatory markers have demonstrated variable sensitivity and specificity across different populations, limiting their widespread clinical utility.

Ultrasonographic assessment has become integral to PPROM management, and recent attention has focused on myometrial thickness (MT) as a potential non-invasive predictor of labor onset and delivery timing. The myometrium undergoes dynamic structural and functional changes throughout pregnancy, with thickness variations reflecting uterine contractility patterns, inflammatory responses, and the risk of imminent delivery. Studies in women with threatened preterm labor have shown that increased MT particularly at the lower uterine segment correlates with heightened uterine activity and a shorter interval to delivery . Ultrasonography provides a non-invasive method for assessing uterine morphology and myometrial activity, with increasing interest in its potential role in predicting the onset of preterm labor.

Despite encouraging preliminary findings, evidence regarding the predictive value of MT in women with PPROM remains limited, and further prospective studies are required before its routine clinical application. Furthermore, in middle-income countries, such as Egypt, where preterm birth remains a major contributor to neonatal morbidity and mortality, the development of accessible, affordable, and non-invasive predictive tools for women with PPROM is of particular clinical importance. The wide availability of ultrasound equipment makes MT measurement a feasible and cost-effective addition to routine PPROM assessment, without requiring specialized biochemical assays or advanced technology.

This study therefore aims to prospectively evaluate the association between MT at multiple uterine sites and the latency interval in women with PPROM. Cut-off values predictive of imminent delivery can be incorporated into clinical management algorithms for this challenging obstetric condition.

Study Type

Observational

Enrollment (Estimated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Pregnant women with preterm prelabor rupture of membranes presenting to Ain Shams University Maternity Hospital.

Description

Inclusion Criteria:

  • Gestational age 28-34 weeks at membrane rupture
  • Presenting to the hospital within 24 hours of PPROM

Exclusion Criteria:

  • Women with contraindications to conservative management. Clinical chorioamnionitis at presentation. Patients presenting in labor Intrauterine fetal death

Medical/Obstetric indications for immediate delivery at presentation:

Severe preeclampsia. Bleeding: placenta previa or placental abruption

  • Women with other risk factors for preterm birth. Fetal growth restriction with lost end-diastolic flow in umbilical artery Known uterine anomalies Multifetal gestation
  • Previous uterine surgery (e.g., myomectomy, classical cesarean section)
  • Morbidly obese women rendering sonographic assessment inaccurate

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Myometrial thickness as a predictor of latency interval in patients with preterm prelabor rupture of membranes
Time Frame: the period from membrane rupture to 24 hours after membrane rupture

Correlation between myometrial thickness at each uterine measurement site and latency interval in patients with preterm prelabor rupture of membranes

the period from membrane rupture to 24 hours after membrane rupture

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Mohamed Serag, Faculty of Medicine - Ain Shams university
  • Study Director: Walid Tantawy, M.D.,, Faculty of Medicine - Modern University for Technology and Information

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 1, 2026

Primary Completion (Estimated)

March 1, 2027

Study Completion (Estimated)

March 1, 2027

Study Registration Dates

First Submitted

September 20, 2026

First Submitted That Met QC Criteria

September 20, 2026

First Posted (Actual)

September 25, 2026

Study Record Updates

Last Update Posted (Actual)

October 6, 2026

Last Update Submitted That Met QC Criteria

October 2, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe